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Abstract: The advent of exponential growth of novel agents tested and approved for the
treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has brought
about a need for understanding of the mechanism of action, side-effects, and clinical efficacy of
these drugs as they relate to these patients. This review will provide a synopsis of the treatment
landscape in mCRPC as varying agents such as abiraterone acetate, cabazitaxel, sipuleucel-T,
radium, and selected emerging agents are presented. A distinct focus on the utilization of
enzalutamide, its mechanism of action, key pivotal trials that brought about its US Food and
Drug Administration approval, as well as patient-focused perspectives and clinical implications
are discussed herein.
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Prostate cancer remains the most common non-cutaneous cancer in the US. In 2014
alone, the projected incidence of prostate cancer is 233,000 cases with deaths occurring in 29,480 men,1 making metastatic prostate cancer therapy truly an unmet medical
need. With the increasing availability of new therapies that brought about a significant
change in the treatment options for metastatic prostate cancer in the last 5 years alone,
issues regarding the optimal sequencing or combination of these agents have arisen.
Currently, several guidelines exist that help direct clinicians as to the best sequencing approach and most would evaluate presence or lack of symptoms, performance
status, as well as burden of disease to help determine the best sequencing for these
agents.2,3 However, therapy failure remains a significant challenge especially since
cross-resistance from each agent is increasingly described.4–6 In addition, patients
may lose the therapeutic window to gain substantial benefit from each drug that has
been proven to provide overall survival gains. Hence, better methods of identifying the
target population who have the most potential to benefit remain an important though
somewhat elusive goal. This review focuses on the landscape of systemic treatment
for prostate cancer with specific attention to enzalutamide, its properties, as well as
other current and selected emerging therapies.

Overview of the current and emerging
treatment options
The rapid evolution of drug therapies in prostate cancer has vastly improved upon the
use of docetaxel since its pivotal US Food and Drug Administration (FDA) approval
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in 2004 and has brought about a new era where progress has
been made beyond the use of androgen deprivation therapy
(ADT) with the addition of novel hormonal agents, immunotherapy, second-line chemotherapy as well as radiopharmaceuticals (see Table 1). The choice of sequencing currently
relies on patient profiles, whether symptoms of metastatic disease exist or not.7,8 Men who are asymptomatic or minimally
symptomatic may benefit from early use of Sipuleucel-T,
while treatment using docetaxel is usually reserved for
patients with pain. Radium is used predominantly for patients
with bony metastases especially in those who are not candidates for aggressive chemotherapy and abiraterone acetate
can be given for effects on pain palliation. Agents such as
cabazitaxel, abiraterone acetate, enzalutamide or radium can
all be offered after progression on docetaxel. While survival
outcomes are undeniably improved with the use of these
therapies, patients’ disease will ultimately progress on each
regimen. The following section gives a brief discussion on
recent drug approvals as commonly utilized in the clinic as
well as selected emerging therapies.

Background on hormonal therapy
Androgens in the form of testosterone or the more potent
dihydrotestosterone (DHT) have been well-defined drivers of progression of prostate cancer and differentiation of
the prostate gland. As such, the backbone of treatment for
advanced prostate cancers was established decades ago when
castration in the form of surgical orchiectomy achieved significant prostate tumor regression.9 Since then, substitution to
chemical castration has been employed mostly due to patient
preference.10 ADT has therefore become the standard systemic
treatment for locally advanced or metastatic prostate cancer.11
While ADT is almost always effective in most patients, disease progression to castration resistance inevitably occurs.12
It is now increasingly recognized that the androgen receptor
(AR) remains overexpressed despite seemingly castrate levels
of testosterone, since alternative receptors may activate the
AR or other target genes may help perpetuate the castrateresistant phenotype,13,14 hence the term “castration-resistance”
has become widely adopted in the literature. The enhanced
understanding of the role of these androgens in stimulating
the growth of prostate cancer has led to the development and
approval of both abiraterone and enzalutamide, the latter of
which will be the main focus of this review.

Abiraterone acetate
The ability to synthesize androgens at multiple sites and
intratumorally brought about the discovery of steroidogenesis
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inhibition as a drug development approach to treat metastatic
castration-resistant prostate cancer (mCRPC).13 Abiraterone
inhibits the microsomal enzyme cytochrome P450 isoform-17
(CYP17) that catalyzes two sequential reactions of
17-α-hydroxylase and 17,20 lyase.15 Abiraterone acetate
was developed as a candidate oral small molecule inhibitor
of CYP17.16–18 The loss of CYP17 as a result of abiraterone
therapy results in augmented cortisol activity which interrupts
negative feedback control of adrenocorticotropic hormone
(ACTH), thereby resulting in increased upstream effectors
with a syndrome of mineralocorticoid excess characterized
by hypokalemia, hypertension and fluid retention,17 which
can be mitigated by addition of low-dose steroids such as
prednisone.19 The subsequent early phase clinical trials
demonstrated feasibility and safety of the use of abiraterone.20–22 The phase III multicenter, randomized trial known
as the COU-AA-30123 ultimately led to US FDA approval
for abiraterone. One thousand one hundred and ninety-five
men with mCRPC who were previously treated and failed
docetaxel were randomized 2:1 to either abiraterone plus
prednisone versus prednisone with placebo.23 The primary
end point of the trial was overall survival (OS), while secondary end points included time to prostate-specific antigen
(PSA) progression, progression-free survival (PFS), and PSA
response rates. The results of the trial marked the first time in
years that an oral, well-tolerated androgen-signaling inhibitor
yielded promising survival benefit. The OS was superior in
the abiraterone acetate arm compared with the prednisone/
placebo arm (14.6 versus 10.9 months; hazard ratio [HR] 0.65;
P,0.001). Similarly, all secondary end points were statistically significant in favor of abiraterone, including time to
PSA progression, PFS, and PSA response rates. Further OS
analysis showed maintained improvement in OS at the time
of reporting (15.8 versus 11.2 months, P,0.0001).24 In COUAA-302, the role of abiraterone in the chemotherapy naive
population was subsequently studied. This phase III randomized, placebo-controlled trial enrolled 1,088 patients with
mildly symptomatic or asymptomatic mCRPC and assigned
to receive prednisone (5 mg twice daily) with 1,000 mg of
abiraterone or placebo.25 The co-primary end points of this
trial were radiographic progression-free survival (rPFS) and
OS, which was met for rPFS, showing benefit in the abiraterone group (16.5 months versus 8.2 months, P,0.0001) but
not for OS, though a strong trend toward improved survival
was seen, but did not cross the O’Brien-Fleming efficacy
boundary for statistical significance or the pre-specified
statistical efficacy boundary (alpha-level: 0.0035).26 Similar
to the earlier study, unblinding was carried out after interim
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Microtubule inhibitor

Semisynthetic taxane inhibiting
microtubule depolymerization and cell
division by binding to tubulin

Selective and irreversible inhibitor
of CYP17

A pure AR signaling inhibitor with no
agonistic properties. Also prevents
the translocation of the AR from
cytoplasm to nucleus, DNA binding,
and co-activator mobilization

An alpha emitter, selectively targets
bone metastases with alpha particles

An autologous cellular immunotherapy
designed to induce an immune response
targeted against PAP, an antigen
expressed in most prostate cancers

Docetaxel +
Prednisone

Cabazitaxel +
Prednisone

Abiraterone +
Prednisone

Enzalutamide

Radium 223

Sipuleucel-T

mCRPC with symptomatic
bone metastases and no
known visceral metastatic
disease. (ALSYMPCA)46
Asymptomatic or minimally
symptomatic patients with
mCRPC (IMPACT)34

mCRPC previously treated
with a docetaxel-containing
regimen (AFFIRM)78
mCRPC not pretreated
with chemotherapy
*(PREVAIL)82

mCRPC previously treated
with a docetaxel-containing
regimen (COU-AA-301)23
mCRPC not pretreated
with chemotherapy
(COU-AA-302)25

mCRPC previously treated
with a docetaxel-containing
regimen (TROPIC)36

mCRPC (TAX327)91

Population studied
(Trial name)

Arm 1: Sipuleucel-T q2 weeks ×3 infusions
Arm 2: Placebo

Arm 1: One injection of radium-223
(at a dose of 50 kBq/kg) IV q4 weeks ×6
Arm 2: Placebo

Arm 1: Enzalutamide 160 mg PO daily
Arm 2: Placebo

Arm 1: Enzalutamide 160 mg PO daily
Arm 2: Placebo

Arm 1: Docetaxel 75 mg/m2 IV q3 weeks +
Prednisone 5 mg PO BID
Arm 2: Mitoxantrone 12 mg/m2 IV q3 weeks +
Prednisone 5 mg PO BID
Arm 1: Cabazitaxel 25 mg/m2 IV q3 weeks +
Prednisone 5 mg PO BID
Arm 2: Mitoxantrone 12 mg/m2 IV q3 weeks +
Prednisone 5 mg PO BID
Arm 1: Abiraterone 1,000 mg PO daily +
Prednisone 5 mg PO BID
Arm 2: Placebo + Prednisone 5 mg PO BID
Arm 1: Abiraterone 1,000 mg PO daily +
Prednisone 5 mg PO BID
Arm 2: Placebo + Prednisone 5 mg PO BID

Intervention

OS benefits: 4.1 months
(25.8 versus 21.7 months)

OS benefit: 30% reduction
in risk of death
rPFS benefit: 81% reduction
in risk of radiographic
progression or death
OS benefit: 3.6 months
(14.9 versus 11.3 months)

rPFS benefit: 8.3 months
(16.5 versus 8.2 months)
OS increased (35.1 versus
30.1 months)**
OS benefit: 4.8 months
(18.4 versus 13.6 months)

OS benefit: 4.6 months
(15.8 versus 11.2 months)

OS benefit: 2.4 months
(15.1 versus 12.7 months)

OS benefit: 2.4 months
(18.9 versus 16.5 months)

Primary end point
outcomes

Infusion-related pyrexia,
myalgia, tremors

Well tolerated with
no clinical meaningful
differences; pancytopenia

Fatigue, diarrhea, hot
flashes, seizures

Mineralocorticoid
excess (fluid retention,
hypertension, hypokalemia)

Neutropenia and diarrhea

Sensory neuropathy

Notable adverse effects

Notes: *PREVAIL study data released, currently awaiting FDA approval; **not statistically significant.
Abbreviations: AFFIRM, A Study Evaluating the Efficacy and Safety of the Investigational Drug MDV3100; ALSYMPCA, Alpharadin in Symptomatic Prostate Cancer Patients; AR, androgen receptor; BID, twice daily; CYP17, microsomal
enzyme cytochrome P450 isoform-17; FDA, US Food and Drug Administration; IMPACT, Immunotherapy for Prostate Adenocarcinoma Treatment;IV, intravenous; mCRPC, metastatic castration-resistant prostate cancer; OS, overall
survival; PO, orally; rPFS, radiographic progression-free survival; PAP, prostatic acid phosphatase; PSA, prostate specific antigen; PFS, progression free survival; q3, every three.

Mechanism of action

Group

Table 1 FDA approved therapies for advanced prostate cancer*
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analysis and cross-over was allowed. There was a notable
delay in chemotherapy administration for the abiraterone
arm at 25.2 months versus 16.2 months in the prednisone
alone arm. These favorable results led to ultimate approval
by the FDA of abiraterone for pre-chemotherapy mCRPC
patients.

Sipuleucel-T
Therapeutic advances for prostate cancer entered a new realm
of treatment possibilities with the advent of immunotherapy.
Identification of certain tumor-associated antigens such as
PSA and prostatic acid phosphatase (PAP) that are overexpressed in prostate cancers provided an attractive target for
immune-based therapies.27,28
Sipuleucel-T is an activated autologous dendritic cellular
vaccine designed to target PAP. The vaccine is manufactured
through ex-vivo stimulation of antigen presenting cells
(APCs) which in turn activate cytotoxic T lymphocytes. It
is an intensive process which entails harvesting a patient’s
own peripheral cells via apheresis. The cells are then exposed
to a fusion peptide consisting of PAP and granulocytemacrophage colony stimulating factor which serves as an
immune adjuvant to enhance immune activation,29 undergo
quality assurance for a minimum of cluster of differentiation
(CD)54 expression threshold for adequate cell collection, and
are subsequently shipped back to an infusion facility where
they can be administered intravenously to the patient every 2
weeks for three infusions.30 With the most common adverse
reactions being transient fever and flu-like symptoms, early
trials of sipuleucel-T demonstrated the safety of this form of
therapy, with no increased risk of autoimmunity.31
Two initial small phase III trials evaluated the ability of
sipuleucel-T to treat minimally symptomatic mCRPC.32,33
By using the conventionally established time to progression
(TTP) end points, the first of these trials failed to meet the primary end point and resulted in the premature discontinuation
of the second small phase III trial. Ultimately, improvement
in the secondary end point of OS was shown, leading to a
second, larger phase III study, with OS as the end point,
coined the IMPACT trial (NCT00065442), which definitively
addressed the clinical benefit of sipuleucel-T in mCRPC.34
Five hundred and twelve patients with minimally symptomatic or asymptomatic mCRPC were enrolled, randomizing
2:1 in favor of sipuleucel-T relative to the placebo. As noted
in the previous studies, there was no significant difference
in TTP based on objective parameters (3.7 months in the
sipuleucel-T arm versus 3.6 months in the placebo arm; HR
0.95; P=0.63). Nonetheless, the findings for OS showed a

654

submit your manuscript | www.dovepress.com

Dovepress

significant advantage for patients treated with sipuleucel-T
at 25.8 versus 21.7 months for placebo, with a 3 year survival
probability of 31.7% versus 23.0% (HR 0.77; P=0.02). These
findings prompted FDA approval of sipuleucel-T for the
treatment of minimally symptomatic mCRPC, ushering in a
modern age of immunotherapy for the treatment of cancer.
An ongoing, phase III trial is evaluating the treatment of
sipuleucel-T in patients with hormone sensitive prostate
cancer (PROTECT), via NCT00779402.

Cabazitaxel
Cabazitaxel is a semisynthetic taxane tested in taxane-resistant
cell lines which inhibits microtubule depolymerization
and cell division by binding to tubulin, resulting in cell
cycle arrest.35 Despite 4 years since its original approval,
cabazitaxel remains the first and only chemotherapy to
have shown a survival benefit as second-line treatment for
patients whose disease has progressed beyond docetaxel. The
approval was based on data from TROPIC,36 a Phase III trial
(NCT00417079) conducted in 755 patients with mCRPC
previously treated with docetaxel; participants were randomized to receive either cabazitaxel or mitoxantrone, both in
combination with prednisone. The primary end point of the
study was OS which was met with patients receiving cabazitaxel achieving a median OS of 15.1 months versus 12.7
months in the mitoxantrone plus prednisone arm; P=0.0001.
The median PFS was also significantly better with cabazitaxel at 2.8 months versus 1.4 months in the mitoxantrone
arm (HR 0.74; P,0.0001). Other secondary end points
such as PSA response, time to PSA progression and tumor
response were all superior in the cabazitaxel over mitoxantrone arms. However, treatment-related deaths were more
frequent in the 30 days after last treatment for cabazitaxel
compared with mitoxantrone (4.9% versus 2.4%). Other
hematologic toxicities, such as neutropenia (82% versus
58%) occurring as a grade 3 event or higher, were much more
often seen in the cabazitaxel arm than mitoxantrone, as was
the non-hematologic toxicity diarrhea (6% versus 1%). In
addition, febrile neutropenia occurred in 8% of patients in
the cabazitaxel group compared with 1% in the mitoxantrone
group. Based on the safety profile, the product label of cabazitaxel had clear safety warnings with regard to monitoring
for neutropenia, and the product label recommended use of
growth factors in high-risk patients, such as those who are
.65 years of age, with extensive prior radiation, or with serious comorbidities and poor nutritional status.37 Conversely,
the rates of neuropathy were certainly favorable and the pain
responses were comparable though not superior to mitoxan-
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trone.38 The perceived hematologic toxicity of cabazitaxel has
limited its clinical use in patients with progressive mCRPC.
Given its place in sequencing in the “post-docetaxel” space,
few patients are deemed fit enough for further chemotherapy
after being heavily pre-treated.

Alpharadin
Radiopharmaceuticals in the form of strontium and
samarium have been available since their FDA approval in
the 1990s, but while early clinical trials with Strontium-89
(Amersham Healthcare, Arlington Heights, IL, USA) and
Samarium-153 (Bayer Healthcare, Berlin, Germany) have
shown pain palliation from skeletal metastases, 39–42 the
absence of significant survival benefit and potential for
myelosuppression has relegated their use for predominantly
palliative end-of-life care.43–45 Alpharadin or radium-223 is
a unique α-emitting radiation agent that served to improve
upon the range of β emitters and was the first in its class of
radiopharmaceuticals to exhibit OS in mCRPC patients with
symptomatic bone metastases.46 Radium-223 emits highenergy alpha particles of short range (,100 µm), inducing
mainly double stranded DNA breaks that result in a potent
and highly localized cytotoxic effect in the target areas.47,48
The shorter travel distance also means fewer toxic effects
on adjacent tissue as well as less myelosuppression.49 Early
clinical trials showed safety and feasibility in prostate cancer
patients,50 eventually leading to the phase III ALSYMPCA
study (NCT00699751) which evaluated 921 men with
mCRPC and bone metastases, comparing radium-223 at
6 monthly injections with placebo, in addition to the best
standard of care.46 The primary end point was met with
a significant improvement in survival for patients treated
with radium-223, with a median OS of 14.9 months versus
11.3 months for placebo, maintained through the updated
analysis.46 All main secondary end points, including time
to first skeletal-related events (SREs) and time to increase
in PSA level showed a benefit of radium-223 as compared
with placebo. This trial ultimately led to the FDA approval
of radium for clinical use in 2013 for predominantly symptomatic men with mCRPC who are post-docetaxel treatment
or intolerant of or ineligible for docetaxel with no known
visceral metastases. The potential for myelosuppression was
low (at 2%) but patients had to have adequate hematologic
parameters prior to starting with radium-223.

Emerging therapies
Several novel agents and treatments have been shown to
have promising effects in earlier phases of prostate cancer
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trials. The challenge continues with how to sequence these
current and emerging therapies,51 especially since many of
the drug approvals have been tested against prior standards
utilizing either placebo, prednisone or mitoxantrone. Hence,
there is increasing difficulty to compare contemporary drugs
with the currently approved landscape of treatment for
mCRPC. We discuss herein a select group of trials that are
in phase III or nearing completion of phase III (see selected
agents in Table 2).

Cabozantinib
Cabozantinib is a novel, orally bioavailable, dual tyrosine
kinase inhibitor with activity against vascular endothelial
growth factor receptor 2 (VEGFR2) and the mesenchymalepithelial transition factor (MET), also known as hepatocyte growth factor receptor, among others. Both MET
and VEGFR2 have been implicated in the progression of
prostate cancer, particularly with bone involvement.52,53
One hundred and seventy-one CRPC patients were included
in a phase II randomized discontinuation trial and were
treated initially with cabozantinib for 12 weeks followed
by continuation of the drug versus placebo for patients who
achieved stable disease. Median PFS for the 31 patients randomized after 12 weeks was 23.9 weeks, versus 5.9 weeks
for those on cabozantinib and placebo.54 After 12 weeks
of the lead-in therapy, 5% had partial responses and 75%
had stable disease, with 72% demonstrating reduction of
soft tissue lesions and 68% with improvements on bone
scan. Sixty-seven percent of available patients reported
an improvement in pain control with a decrease in, or
discontinuation use of narcotics by 56%. In a subsequent
dose-finding study, cabozantinib at a lower dose, 40 mg
compared with 100 mg, was found to be better tolerated
with similar clinical effect.55
These encouraging results have prompted two phase III
trials. COMET-1 (NCT01605227), with a primary end point
of OS is a placebo-controlled trial enrolling 960 men with
mCRPC and additional prior therapy, randomly assigned to
prednisone or cabozantinib. COMET-2 (NCT01522443) is
a placebo-controlled phase III trial evaluating cabozantinib
versus mitoxantrone and prednisone in patients with previously treated symptomatic mCRPC, with an emphasis on the
effect on pain and bone disease.

Tasquinimod
Tasquinimod, a quinolone-3-carboxamide, with antiangiogenic,
immunomodulatory, and anti-metastatic properties has previously demonstrated preclinical evidence of antitumor activity
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Oral, dual tyrosine kinase inhibitor
with activity against VEGFR2 and
MET

Monoclonal antibody blocking
CTLA-4

Oral, quinoline-3-carboxamide
derivative that binds to S100A9, an
immunomodulatory protein that
promotes tumor development
Oral competitive androgen
receptor antagonist

Selective inhibitor of the 17,20
lyase activity of CYP17A1

Second generation antisense
oligonucleotide known to suppress
clusterin levels

Comprised of two poxviral vectors:
vaccinia and fowlpox viruses,
modified to express PSA

Cabozantinib

Ipilimumab

Tasquinimod

Orteronel
(TAK-700)

Custirsen sodium
(OGX-111)

Prostvac V/F

Arm 1: Docetaxel + Prednisone +
Custirsen sodium
Arm 2: Docetaxel + Prednisone

Arm 1: Cabazitaxel + Prednisone +
Custirsen sodium
Arm 2: Cabazitaxel + Prednisone
Arm 1: Prostvac V/F + GM-CSF
Arm 2: Prostvac V/F + GM-CSF Placebo
Arm 3: double placebo

Second line chemotherapy in men
with metastatic castration-resistant
prostate cancer
Asymptomatic or minimally
symptomatic, metastatic castrationresistant prostate cancer

Arm 1: Orteronel + Prednisone
Arm 2: placebo + Prednisone

Arm 1: ARN-509
Arm 2: placebo

Arm 1: Tasquinimod
Arm 2: placebo

Primary: OS
Secondary: proportion of event free
patients compared with placebo

Primary: metastasis-free survival
Secondary: OS; TTSP; TTCC; rPFS; TTM;
FACT-P and EQ-5D questionnaire
scores; # of patients affected by adverse
events; plasma drug and metabolite
concentrations
Primary: OS; negative trial for OS90
Secondary: 50% PSA response at
12 weeks; pain response at 12 weeks; rPFS
Primary: OS; preliminary report
negative: median OS 23.4 months arm
1 vs 22.2 months arm 2 (P=0.2)
Secondary: PFS at day 140; safety profile;
PFS at day 225; PSA measurements
Primary: OS
Secondary: PFS at day 140

Primary: PFS

NCT01322490

NCT01578655

NCT01188187

NCT01193257

NCT01946204

NCT01234311

NCT01057810

NCT01522443

Primary: confirmed pain response at
week 12 durable since week 6
Secondary: bone scan response

Primary: OS
Secondary: PFS; time to pain progression;
finished accrual, awaiting results

NCT01605227

Primary: OS
Secondary: bone scan response

Arm 1: Cabozantinib + placebo
matched Prednisone
Arm 2: Prednisone + placebo
matched Cabozantinib
Arm 1: Cabozantinib + placebo
matched Prednisone + placebo
Mitoxantrone injections
Arm 2: Mitoxantrone + Prednisone +
placebo Cabozantinib
Arm 1: Ipilimumab
Arm 2: placebo

NCT

End point classification

Intervention

First line chemotherapy in men
with metastatic castration-resistant
prostate cancer

Metastatic castration-resistant
prostate cancer post-docetaxel

Non-metastatic (M0) castrationresistant prostate cancer

Asymptomatic or minimally
symptomatic patients with
metastatic chemotherapy-naïve
castration-resistant prostate cancer
Metastatic castration-resistant
prostate cancer

Men with metastatic castrationresistant prostate cancer
previously treated with docetaxel
and abiraterone or MDV3100
Men with previously treated
symptomatic castration-resistant
prostate cancer

Population

Notes: Cabozantinib; Exelixis, San Francisco, CA, USA. Ipilimumab; Bristol-Myers Squibb, New York, NY, USA. Tasquinimod; Active Biotech Research AB, Lund, Sweden. ARN-509; Aragon Pharmaceuticals, San Diego, CA, USA. Orteronel;
Takeda Pharmaceuticals USA, Deerfield, IL, USA. Custirsen sodium; OncoGeneX Pharmaceuticals, Bothell, WA, USA. Prostvac-V/F; Bavarian Nordic, Inc., Mountain View, CA, USA. MDV3100; Medivation, San Francisco, CA, USA.
Abbreviations: VEGFR2, vascular endothelial growth factor receptor 2; MET, mesenchymal-epithelial transition factor; CTLA-4, cytotoxic T-lymphocyte antigen 4; OS, overall survival; TTSP, time to symptomatic progression; TTCC, time
to initiation of cytotoxic chemotherapy; rPFS, radiographic progression free survival; TTM, time to metastasis; PSA, prostate specific antigen; PFS, progression free survival; vs, versus; CYP, cytochrome P; FACT-P,Functional Assessment of
Cancer Therapy-Prostate; GM-CSF, granulocyte-macrophage colony stimulating factor; MDV, medivation; EQ-5D. European quality of life tool.

ARN-509

Mechanism of action

Group

Table 2 Selected emerging therapies currently in phase III clinical trials
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in prostate cancer.56,57 A phase I trial of tasquinimod in patients
with chemotherapy-naïve CRPC showed common adverse
events including inflammation, nausea, and fatigue.58 Rare
but serious adverse events included sinus tachycardia, cerebral
infarction, and hyperamylasemia. More recently, an international, double-blinded, phase II trial enrolled 201 men who
were randomized in a 2:1 fashion for therapy with tasquinimod
or placebo. Although there were no significant changes in
PSA progression in the two arms of the trial, rPFS favored
the tasquinimod arm (7.6 versus 3.3 months; P=0.0042).59
Patients whose cancer had already metastasized to their
bones and who took tasquinimod remained progression-free
for even longer – 8.8 months, compared with 3.4 months
for placebo. Currently, a phase III study (NCT01234311) of
tasquinimod versus placebo is enrolling mCRPC patients in
order to determine its true efficacy in mCRPC.

Ipilimumab
Ipilimumab is a monoclonal antibody that binds to cytotoxic
T lymphocyte antigen 4 (CTLA-4), a molecule expressed on
cytotoxic T lymphocytes after activation by antigen-presenting cells.60 Ipilimumab serves as a checkpoint inhibitor that
overcomes immune activity T cell suppression to enable a
more enhanced anti-tumor immune response.
CA184-043 was a phase III trial comparing ipilimumab
given at 10 mg/kg to placebo, following radiotherapy to
stimulate immune priming in patients with mCRPC, who
have received and failed prior treatment with docetaxel.61 The
study’s primary end point of OS did not reach statistical significance with a median OS of 11.2 months (95% CI 9.5–12.7)
for ipilimumab and 10.0 months (95% CI 8.3–11.0)
for placebo (HR 0.85; 95% CI 0.72–1.00; P=0.053).
However, benefit was observed across some efficacy end
points in a post-hoc assessment of predefined subgroups
of patients with favorable features, such as those without
visceral metastases, alkaline phosphatase , 1.5× normal, or
a hemoglobin of 110 g/L or higher.62 Ipilimumab was also
tested in asymptomatic or minimally symptomatic patients
with chemotherapy-naïve mCRPC (NCT01057810). The trial
has finished accrual and awaiting results.

Review of pharmacology, mode
of action, and pharmacokinetics
of enzalutamide
Enzalutamide, a small molecule AR antagonist is a once
daily second generation AR signaling inhibitor that was
approved by the FDA in 2012 for the treatment of mCRPC
post-chemotherapy with docetaxel.63 Given that the AR
transcription program remains active despite emergence of
Therapeutics and Clinical Risk Management 2014:10

Advanced prostate cancer

castration resistance,64 this property has been exploited to
screen for anti-androgens with specific ability to bind and
inhibit the AR without the agonistic effects.65
Enzalutamide was selected for development based
on research done at Sawyers’ laboratory66 (University of
California, Los Angeles, CA, USA) where RD162 and
MDV3100 were identified as nonsteroidal diarylthiohydantoin agonists, from amongst 200 derivatives, from the activity matched with the chemical structure. Enzalutamide was
further selected as the lead candidate due to its high affinity
and selectivity for the ligand binding domain of the AR,
despite increased AR expression, and used for further clinical studies.66 The clinical development of enzalutamide was
spearheaded by Medivation, Inc. (San Francisco, CA, USA)
in 2007. Enzalutamide was unique from first generation AR
antagonists, since it lacked significant agonist activity, as it
inhibited PSA induction as well as multiple steps in the AR
signaling pathway. The first action of enzalutamide blocks
binding of testosterone to the AR and blocks the conformational change induced by AR-testosterone binding (see
Figure 1). Enzalutamide has approximately five to eight-fold
higher binding affinity to AR than the first generation antiandrogen bicalutamide. The second action of enzalutamide
reduces nuclear translocation of the AR and results in a significant fraction of the AR remaining in the cytoplasm. The
remaining actions of enzalutamide include impairment of
AR DNA binding and interference with co-activator recruitment, which ultimately results in decreased cell growth and
apoptosis leading to decreased prostatic tumor volume.

Pharmacokinetics
Enzalutamide has as its active metabolite, N-desmethyl
enzalutamide. The pharmacokinetics have been described both
in patients with mCRPC following an oral administration of
160 mg/day and in healthy male volunteers following a single
oral administration of 160 mg with or without a fatty meal.67

Absorption and distribution
Enzalutamide was rapidly and well absorbed after oral
administration, with absorption estimated to be 84% of the
administered dose.69 The drug had a median time to maximum
concentration (Cmax) of 1 hour (range of 30 minutes to 3 hours)
and steady state plasma concentrations were achieved by day
28 of daily treatment with low daily fluctuations in plasma
concentrations. After reaching the steady state, the mean
plasma Cmax was 16.6 µg/mL for enzalutamide and 12.7 µg/mL
for N-desmethyl enzalutamide with plasma mean pre-dose
trough values of 11.4 and 13.0 µg/mL, respectively. The coefficient of variation was #30% for these values. The plasma
submit your manuscript | www.dovepress.com
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Androgen receptor (AR)

Testosterone (T)

Enzalutamide

AR after conformational change
due to testosterone binding
1. Enzalutamide competitively
inhibits AR-T binding
2. Enzalutamide blocks the
activational change induced
by AR-T binding

Cell membrane

Nucleus

3. Enzalutamide inhibits AR-T
nuclear translocation and DNA
transcription
Figure 1 Mechanism of action of enzalutamide.
Note: Enzalutamide inhibits binding of testosterone to the AR, prevents translocation, impairment of AR DNA binding, and interference with co-activator recruitment and
DNA transcription.

enzalutamide level is not affected by the dose up to 600 mg
per day.68 The mean peak to trough ratio in enzalutamide
plasma concentration was 1.25, indicating a low daily fluctuation in concentration. During a 1 year period of ongoing
enzalutamide therapy, the pre-dose minimum concentration
of enzalutamide and its active metabolite remained constant.
Similarly, the area under the concentration-time curves was
notably similar in healthy volunteers after a single 160 mg oral
dose either fasting or with a high fat meal. Thus, enzalutamide
can be taken with or without food. The mean apparent volume
of distribution after a single dose is 110 L, which indicates
extensive extravascular distribution. The majority (97%) of
enzalutamide binds to albumin, and 95% of N-desmethyl
enzalutamide binds to plasma proteins.

Metabolism and elimination
Enzalutamide has several potential drug interactions owing
to its metabolism. The drug is mainly metabolized by the
liver cytochrome P450 system, specifically in vitro human
CYP3A4 and CYP2C8, the latter of which is primarily
responsible for the formation of the active metabolite,
N-desmethyl enzalutamide. After administration of a single
dose of radioactive enzalutamide, radioactivity was detected
in the plasma as enzalutamide, N-desmethyl enzalutamide,
and carboxylic acid (an inactive metabolite). Metabolism of
enzalutamide may be modified by concomitant administration
of drugs that induce CYP2C8 or CYP3A4. Enzalutamide
is a strong inducer of CYP3A4 and a moderate inducer of
CYP2C19 and CYP2C9, and inhibits P glycoprotein.
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Enzalutamide is cleared predominantly via hepatic
metabolism, being excreted 71% in the urine and 14% in the
feces, primarily as an inactive metabolite. Enzalutamide’s
mean total plasma clearance is 0.56 L/hour and the mean
terminal half-life is 5.8 days. The mean terminal half-life for
N-desmethyl enzalutamide was about 8 days.
There were no clinically important effects of age or body
weight on enzalutamide pharmacokinetics. Insufficient data in
non-Caucasian populations exist to evaluate pharmacokinetic
differences based on race. The apparent clearance and composite area under the curve of enzalutamide was similar in
patients with pre-existing mild and moderate renal impairment (creatinine clearance $30 mL/minute) and mild to
moderate hepatic impairment (Child-Pugh Class A and B)
when compared to volunteers with normal renal and hepatic
function, based on a population pharmacokinetic analysis.69
While no studies have included patients with severe hepatic
or renal impairment, no adjustments for initial dosing were
suggested for patients with mild to moderate renal or hepatic
impairment,69 making the use of enzalutamide attractive for
patients with such dysfunction.

Efficacy, safety, and tolerability
studies, including comparative
studies
Given the inevitable resistance or progression to firstgeneration AR inhibitors that limits effective prostate
cancer therapy, efforts to investigate resistance patterns and
mechanisms to these inhibitors have evolved. The partial
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agonist activity seen with the older-generation AR inhibitors
and the greater binding affinity of the more potent androgen
DHT lend insights into the design of second-generation
anti-androgens.70,71 While earlier AR inhibitors such as
bicalutamide or flutamide have demonstrated PSA responses,
improvement in OS was uniformly lacking.72–74
Early preclinical trials with enzalutamide showed greater
affinity with lower nanomolar concentrations required for
binding, compared to earlier generations of anti-androgens such as bicalutamide. Given enzalutamide’s greater
affinity relative to bicalutamide as well as its function as a
pure AR antagonist,75 though there has been emerging small
reports of possible enzalutamide withdrawal responses,76
initiation of a phase I/II trial in humans was undertaken.
The initial phase I/II trial enrolled 140 patients with
mCRPC across five centers in the US, 78% of whom had
metastatic disease, and they received enzalutamide orally at
varying daily doses (range: 30–600 mg).67 The trial sought to
establish the safety, tolerability, and anti-tumor effects with
positron emission tomography (PET) scan and circulating
tumor cell (CTC) correlation.
The patients were relatively heavily pre-treated, with
nearly half of the patients having had prior chemotherapy,
and over three-quarters of patients having received at least
two lines of hormonal therapy, with 45% having prior ketoconazole exposure. Antitumor activity was observed at all
tested dosages, including stabilized bone disease in 61 (56%)
of 109 patients, .50% or more declines in PSA in 78 (56%)
patients, soft tissue responses in 13 (22%) of 59 patients
and conversion from unfavorable to favorable CTC counts
in 25 (49%) of the 51 patients, signifying a favorable effect
in this adverse prognostic group of patients. PSA responses
were similar between those who received prior chemotherapy
versus not. The maximum tolerated dose for sustained treatment (.28 days) was 240 mg and no additional benefit was
obtained from higher dosages, and the tested dose later used
for the phase III trial was 160 mg. There was a beneficial
effect on objective radiological regression with an observed
47 weeks of median time to radiological progression for
all patients, although it was notably more prolonged in the
chemotherapy-naïve group (60 weeks compared to the chemotherapy pre-treated group at 29 weeks). There were no
safety concerns in this early study but of note, three patients
who developed seizures were receiving 360 mg, 480 mg, and
600 mg, respectively. Efforts to determine any risk factors
unveiled two of these patients were on medications that lowered the seizure threshold. Hence later exclusion in the phase
III AFFIRM (A Study Evaluating the Efficacy and Safety of
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the Investigational Drug MDV3100) trial of patients with any
risk factors that may lower such seizure threshold, such as a
history of prior stroke, aneurysms, concomitant medications
that lower seizure thresholds. At longer follow-up and at the
time of updated analysis, 18 of the enrolled patients remained
in the study, with a median time on therapy of 131 weeks.77

Phase III study: the AFFIRM trial
The phase 3 AFFIRM trial was a randomized, double-blind,
placebo-controlled, international trial evaluating enzalutamide
at 160 mg/day versus placebo in 1,199 men with advanced
prostate cancer who were previously treated with docetaxelbased chemotherapy.78 Distinct from the COU-AA-301
or COU-AA-302 trials, steroids were not mandated but
allowed at study entry and were found to be used in a third
of patients, in both arms. The trial had OS as its primary end
point with secondary end points of radiographic PFS, time
to PSA progression, quality of life (QoL), and time to the
first SRE. Given analysis showing improved OS favoring
enzalutamide, the Data and Safety Monitoring Committee
recommended halting the trial and patients on placebo were
offered to cross over to receive enzalutamide, although only
about 19 patients (5%) still remained on placebo at the time of
unblinding. At a median follow-up of 14 months, the median
OS was still significantly improved in the enzalutamide arm
versus the placebo arm (18.4 months versus 13.6 months,
respectively; HR, 0.63; 95% confidence interval [CI], 0.53–
0.75; P,0.001). This translated to a 37% reduction in the risk
of death of any cause in the enzalutamide arm. The efficacy
of enzalutamide translated across all other end points, such
as time to PSA progression (8.3 versus 3 months), median
rPFS (8.3 versus 2.9 months), and risk-categories. Overall
response rates (ORRs) via Response Evaluation Criteria In
Solid Tumors (RECIST) was also significantly different at
29% in the enzalutamide arm compared to 4% in the placebo arm (P,0.001). The effects on pain and SREs showed
improvement in the time to first SRE, as 16.7 months versus
13.3 months; HR, 0.62; P,0.001. Given the use of steroids
in about a third of patients, a highlighted difference from the
COU-AA-301 and COU-AA-302 trials wherein all patients
were on steroids, further post hoc analysis was examined
and found that patients who were on steroids upon study
entry had worse survival compared to those who were not on
steroids,79 suggesting the potential detrimental role of glucocorticoid receptor expression as a means of resistance seen
in enzalutamide therapy,80 though potentially confounded by
a patient population that could have been more symptomatic,
hence the need for steroid use in the first place. The positive
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findings seen from the AFFIRM trial became instrumental in
the subsequent FDA approval of enzalutamide for men with
mCRPC who have failed prior chemotherapy.

Phase III study: PREVAIL
At the 2014 American Society of Clinical Oncology Genitourinary Cancers Symposium, data from the much anticipated
phase III PREVAIL study (A Safety and Efficacy Study of Oral
MDV3100 in Chemotherapy-Naive Patients With Progressive
Metastatic Prostate Cancer) was presented,81 and is now published.82 PREVAIL was a double-blinded, international, placebocontrolled trial that enrolled 1,717 chemotherapy-naïve mCRPC
patients who were stratified by site and given enzalutamide 160
mg/day or placebo in a 1:1 fashion. The co-primary end points
included OS and radiographic PFS. The findings were strikingly
positive with statistical improvement in the OS of 32.4 months
in the enzalutamide arm versus 30.2 months in the placebo
arm. The co-primary end point of median rPFS was similarly
superior and was not reached (95% CI: 13.8 – upper limit not
reached) in the enzalutamide arm versus only 3.9 months (95%
CI: 3.7–5.4) in those who received placebo, upon reporting of the
trial. There was a corresponding 29% reduction in risk of death
for the enzalutamide arm compared to placebo (OS: HR 0.706;
95% CI: 0.59–0.83; P,0.0001) and an 81% reduction in risk
of radiographic progression or death (rPFS: HR 0.19; 95% CI:
0.15–0.23; P,0.0001). Given these findings, the Independent
Data Monitoring Committee recommended halting the study and
study patients were offered a cross over from placebo to enzalutamide. It is also interesting to note that the use of enzalutamide
delayed the median time to the institution of chemotherapy by
about 17 months, with a time to chemotherapy at 28 months in
the enzalutamide arm versus 10.8 months in the placebo arm
(HR 0.35; 95% CI:0.3–0.4; P,0.0001).
Certain differences in trial characteristics between the
Cougar abiraterone studies23,25 compared to the enzalutamide
trials can be noted. While the abiraterone COU-AA-302
trial excluded men with visceral disease, the PREVAIL trial
included about 11.2% of patients with visceral metastases.
The median time to delay in chemotherapy was about
17 months in the PREVAIL trial versus 8.4 months in the
COU-AA-302 trial although the latter used prednisone as the
control arm, rather than just placebo.

Patterns of resistance
While the results from both AFFIRM and PREVAIL studies
are both unprecedented, questions remain as to the proper
sequencing of these agents.51 It is increasingly recognized
that responses of enzalutamide are modest post-abiraterone
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use and the issue of cross-resistance is increasingly being
recognized.83 In one retrospective multicenter trial that
included 183 men who had received prior abiraterone, about
30% of men who had no significant prior response to abiraterone still achieved response to enzalutamide.84 However,
overall responses are still modest. There is increasing recognition that emergence of splice variants in the AR, AR
mutations especially in the ligand binding domain, confers
resistance to enzalutamide.85 This has become an active area
of research with determination of splice variants such as
AR-V7 that may help discern the patients who may or may
not respond to enzalutamide, as well as development of novel
therapeutics to inhibit such variants.86

Safety and tolerability
Enzalutamide appears to be generally well tolerated at the administered 160 mg/day dose employed in the phase III trials. There
were a few toxicities noted in the AFFIRM study that were more
common in the enzalutamide arm,78 including fatigue (all grades,
34% versus 29.1%), diarrhea, musculoskeletal pain, headache,
hypertension, and hot flashes. The patients on the enzalutamide
arm had a lower incidence of grade 3–4 adverse events; 45.3%,
versus 53.1% in the placebo group. One adverse event of note
was the occurrence of seizures which was reported in five
patients in the enzalutamide arm (versus none in the placebo
arm) during the phase III AFFIRM trial with another two seizure
events reported in the follow-up data. This occurrence was noted
despite exclusion of patients in the AFFIRM trial with known
predisposition to seizures, such as those with recent history of
cerebrovascular accidents, febrile seizures, transient ischemic
attacks within the past 12 months, and even use of certain drugs
that could lower seizure threshold or prolong QT interval such
as insulin, tricyclic anti-depressants, antiarrhythmics, among
others. Certain risk factors for decreasing the seizure threshold
have been identified in these studies as a potential explanation
for occurrence of seizures. Of the five patients who experienced
seizures, one received lidocaine, one patient had brain atrophy
due to alcohol, and two had brain metastases. Including the
two patients who experienced seizures in the longer follow-up
of the AFFIRM study, the overall combined seizure risk was
about 1%. The PREVAIL trial showed reported seizure events
in only two patients.81

Patient focused perspectives:
quality of life, patient satisfaction/
acceptability and adherence
Health related QoL is increasingly incorporated in clinical
trials as one of multiple end points being assessed.
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This is particularly true in diseases with a poor prognosis like
mCRPC where QoL, and not just efficacy alone, may be of
significant importance and relevance to the patient and family,
as well as the treating physicians. Prostate cancer significantly
affects QoL in many patients especially given pain-related
symptoms due to bone metastases and treatment-related
issues like urinary, sexual, bowel, and hormonal functions,
which when affected, greatly influence satisfaction of the
patients and their families with treatment outcome.87
Although assessing QoL is not as objective as assessing OS or radiographic tumor response, many tools are
being used to assess QoL in patients with various tumors
and many of these tools are validated and used in a wide
array of studies. One such tool is the use of the Functional
Assessment of Cancer Therapy-Prostate (FACT-P). FACT-P
is a QoL instrument used with prostate cancer patients which
assesses patients in the physical, social/family, emotional, and
functional well-being domains. Combining all four modalities scores represents a global QoL score with higher scores
representing better QoL response.
Nearly all prostate cancer patients with metastatic disease will become castration-resistant at some point during
the course of their disease. Therefore, research has focused
on finding drugs that will serve to increase not only survival
but QoL. Of the medications that are proven to increase
survival in mCRPC, as well as QoL parameters (docetaxel,
cabazitaxel, sipuleucel-T, radium 223, abiraterone acetate,
and enzalutamide), abiraterone and enzalutamide are
the only orally-available medications and have favorable
safety profiles. Hence, these agents are being increasingly
and favorably used by physicians. Therefore, assessing
QoL measures in these two medications is of significant
importance.
The two studies that showed improvement in OS and
studied QoL measures with abiraterone are the COU AA-301
(post-docetaxel) and COU AA-302 (pre-docetaxel). In the
COU AA-301 trial,23 the rate of pain palliation was significantly better with abiraterone/prednisone versus prednisone
alone (44% versus 27%, P=0.002) and the median time to
FACT-P total scale deterioration was also significantly better
with abiraterone (14 months versus 8.4 months, HR 0.607,
P,0.0001).88 In the COU AA-302, median time to increased
pain was significantly better with abiraterone versus prednisone (26.7 months versus 18.4 months, HR 0.82, P=0.049)
and median time to opiate use was significantly delayed with
abiraterone. As for the median time to FACT-P score deterioration, it was 12.7 months versus 8.3 months (HR 0.78,
P=0.003) in favor of abiraterone.25
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Enzalutamide was also studied in the pre-docetaxel
(PREVAIL) and post-docetaxel (AFFIRM) chemotherapy trials with positive results with respect to OS and QoL measures
when compared to placebo. In the AFFIRM trial, FACT-P
QoL response was significantly better with enzalutamide
compared to placebo (43% versus 18%, P,0.001).78 The
median time to pain progression on the FACT-P scale was
not reached for enzalutamide versus 13.8 months for placebo
(HR 0.56, P=0.0004).89 Pain palliation, defined as more than
30% reduction in median pain score after 12 weeks of treatment compared with pretreatment pain score without more
than 30% increase in use of opiates, was achieved in 45% of
patients on enzalutamide versus 7% of patients on placebo.
Results of the PREVAIL study reported that the median
time to FACT-P global score decline was 11.3 months versus
5.6 months in favor of enzalutamide versus placebo with HR
0.625 and P,0.0001.81

Conclusion
Substantial evidence exists for improving not only the
rigorous end points of OS, rPFS but also pain and QoL data
with the use of these newer agents for mCRPC. However,
much work remains to be done with trying to overcome
resistance and choice of sequencing of these agents. Decision about which therapy comes first and the designation
of terms such as “pre-docetaxel” or “post-docetaxel” are
arbitrary since the timing of the FDA approval of drugs currently dictates practice pattern of which agents are being used
first. Once resistance occurs, it is unclear whether subsequent
regimens would exert the same benefit, since randomized
head-to-head comparisons do not exist for these currently
available drugs. Much is therefore left to the clinicians to
determine factors such as patients’ comorbidities, pace of
disease progression, presence of predominantly bone or
visceral metastases, symptoms, toxicity profile, patient preference, cost, and accessibility, to enable making appropriate
decisions about choice of therapy.
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